Roche Ramps Up Cancer Portfolio With $1.7bn Ignyta Buy

 
• By Kevin Grogan

The Swiss giant's acquisition of Ignyta to get hold of the latter's closely-watched NSCLC drug entrectinib will potentially trigger an intriguing fight for market share in the near future with Loxo Oncology and Bayer's larotrectinib.

Santa cap
Nice present: Ignyta is being acquired by Roche for $1.7bn • Source: Shutterstock

More from Deals

More from Business